NielsenIQ (NIQ) Unleashes the Power of a Connected User Experience With Consumer Panel and Retail Measurement Data Integrated on the NIQ Discover Platform
10.7.2024 16:00:00 EEST | Business Wire | Press release
NielsenIQ (NIQ) today announced the launch of an integrated user experience for its Consumer Panel clients globally. This brings the Full View of Retail measurement and Consumer Panel data to life on a single platform, NIQ Discover. With a focus on elevating the client experience, the Discover platform leverages a new cloud-based architecture and aggregation engine providing faster data accessibility and user flexibility.
NIQ's Discover platform for Consumer Panel is set to transform the consumer insights landscape. With its advanced analytical models and always-on capabilities, NIQ is leading the way in delivering actionable insights. Clients can now enjoy a modern and intuitive interface that enhances their interaction with the platform, opening endless possibilities to analyze consumer behaviors to drive growth. “NIQ has made significant investments in our global consumer panel capabilities in the past year, enhancing performance, quality and usability of data driven insights. The launch of this modern, cloud-based platform is one of several enhancements we are making to our Consumer Panel offerings globally. Clients will now get access to panel data together with retail measurement, delivering a connected user experience,” said Kris Ewing, President, Global Consumer Panel Services, NIQ.
Key benefits of NIQ Discover platform for Consumer Panel include:
- Elevated user experience: On-demand insights unlocked through an intuitive and powerful visualization experience, side-by-side with retail measurement data, enabling seamless, guided flows that cross complementary data sets.
- Flexibility: Clients can build their own analyses and get results on-the-fly, opening a world of possibilities across different dimensions of people groups, facts, products, retailers, geographies, periods and demographics.
- On-demand Data: Access to advanced analytical models elevates the data analysis experience seamlessly within seconds. Clients can access key performance indicators like penetration in addition to more sophisticated analytical models like Super Shifting, Key Item Ranking, Assortment Optimizer and Portfolio Trial and Repeat
- Gen AI-driven insights through NIQ Ask Arthur: Consumer panel on NIQ Discover enables users to leverage NIQ Ask Arthur, a groundbreaking Gen AI-driven tool, to aid in global search, streamline data analysis and facilitate informed decision-making.
NIQ’s Consumer Panel Services (CPS) provides the most complete and clear view of today’s consumers across 23 markets. Some of the enhancements NIQ is making to its Consumer Panel include:
- Expansion of panel sample sizes globally, with broader coverage and representation across North America, West Europe, and Pacific.
- The best data: Delivering the Full View of consumer behavior across retail channels and brands with panel quality and coverage the industry trusts.
- Expanded analytical capacity through industry-leading consumer experts who bring powerful insights to life, connecting NIQ’s Retail Measurement data, Consumer Panel and other NIQ offerings to drive growth for CPG and retailer clients.
NIQ Discover for CPS provides an unparalleled user experience, delivering the best quality, the widest coverage, and most sophisticated analytics all in a single platform. It redefines the way clients can harness the analytical power of NIQ data and elevate insights to unprecedented heights.
About NIQ
NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710255063/en/
Contacts
sweta.patra@nielseniq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 10:00:00 EEST | Press release
ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom